Hopes raised just over a month ago by encouraging interim Phase IIb data with aldoxorubicin (aldox) in soft-tissue sarcomas (STS) were met and then some by Cytrx Corp., which disclosed top-line results that show an 80 percent to 100 percent improvement in progression-free survival (PFS) with the compound.